Hannah Robinson
Clinical Operations Director
I have a background in paediatric nursing and have worked in research at Oxford Vaccine Group since 2008.
I supervise and support the clinical teams and make sure the UK clinical trials are run safely, effectively and efficiently from a clinical perspective. With other senior members of the group I make sure our processes are up to date and work well. A large part of my role is looking at the feasibility of OVG's planned research and when and how it can be delivered.
Recent publications
-
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.
El Safadi D. et al, (2025), J Infect Dis, 231, e17 - e27
-
Single-cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.
Zivanovic N. et al, (2023), Clin Transl Med, 13
-
Salmonella Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort.
Hanumunthadu B. et al, (2023), BMJ Open, 13
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
-
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Flaxman A. et al, (2021), Lancet, 398, 981 - 990